INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation
FRA:IUI1 • US46120E6023
Current stock price
407.1 EUR
-8.65 (-2.08%)
Last:
This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IUI1.DE Profitability Analysis
1.1 Basic Checks
- In the past year IUI1 was profitable.
- In the past year IUI1 had a positive cash flow from operations.
- Each year in the past 5 years IUI1 has been profitable.
- Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of IUI1 (13.96%) is better than 96.77% of its industry peers.
- Looking at the Return On Equity, with a value of 16.02%, IUI1 belongs to the top of the industry, outperforming 88.71% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 13.95%, IUI1 belongs to the best of the industry, outperforming 91.94% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is above the industry average of 10.01%.
- The last Return On Invested Capital (13.95%) for IUI1 is above the 3 year average (12.43%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROIC | 13.95% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
1.3 Margins
- IUI1 has a better Profit Margin (28.38%) than 100.00% of its industry peers.
- IUI1's Profit Margin has improved in the last couple of years.
- With an excellent Operating Margin value of 29.35%, IUI1 belongs to the best of the industry, outperforming 98.39% of the companies in the same industry.
- In the last couple of years the Operating Margin of IUI1 has grown nicely.
- IUI1 has a better Gross Margin (66.00%) than 74.19% of its industry peers.
- IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% |
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
2. IUI1.DE Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
- The number of shares outstanding for IUI1 has been reduced compared to 1 year ago.
- Compared to 5 years ago, IUI1 has more shares outstanding
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- IUI1 has an Altman-Z score of 40.01. This indicates that IUI1 is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 40.01, IUI1 belongs to the best of the industry, outperforming 98.39% of the companies in the same industry.
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 40.01 |
ROIC/WACC1.32
WACC10.59%
2.3 Liquidity
- A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
- The Current ratio of IUI1 (4.87) is better than 96.77% of its industry peers.
- A Quick Ratio of 3.96 indicates that IUI1 has no problem at all paying its short term obligations.
- IUI1 has a better Quick ratio (3.96) than 96.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 |
3. IUI1.DE Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 21.83% over the past year.
- Measured over the past years, IUI1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 21.42% on average per year.
- IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.51%.
- The Revenue has been growing by 18.22% on average over the past years. This is quite good.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
3.2 Future
- Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.58% on average per year.
- The Revenue is expected to grow by 12.90% on average over the next years. This is quite good.
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. IUI1.DE Valuation Analysis
4.1 Price/Earnings Ratio
- IUI1 is valuated quite expensively with a Price/Earnings ratio of 52.73.
- IUI1's Price/Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 61.29% of the companies in the same industry.
- IUI1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.50.
- Based on the Price/Forward Earnings ratio of 46.09, the valuation of IUI1 can be described as expensive.
- 67.74% of the companies in the same industry are cheaper than IUI1, based on the Price/Forward Earnings ratio.
- IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.67.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.73 | ||
| Fwd PE | 46.09 |
4.2 Price Multiples
- 64.52% of the companies in the same industry are cheaper than IUI1, based on the Enterprise Value to EBITDA ratio.
- The rest of the industry has a similar Price/Free Cash Flow ratio as IUI1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 67.18 | ||
| EV/EBITDA | 43.68 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as IUI1's earnings are expected to grow with 14.52% in the coming years.
PEG (NY)3.65
PEG (5Y)2.46
EPS Next 2Y14.34%
EPS Next 3Y14.52%
5. IUI1.DE Dividend Analysis
5.1 Amount
- IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IUI1.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IUI1 (3/24/2026, 7:00:00 PM)
407.1
-8.65 (-2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22 2026-01-22/amc
Earnings (Next)04-20 2026-04-20/amc
Inst Owners88.53%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap144.59B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts78.1
Price Target527.49 (29.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)-1.16%
PT rev (3m)0.59%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.73 | ||
| Fwd PE | 46.09 | ||
| P/S | 16.62 | ||
| P/FCF | 67.18 | ||
| P/OCF | 55.21 | ||
| P/B | 9.39 | ||
| P/tB | 9.6 | ||
| EV/EBITDA | 43.68 |
EPS(TTM)7.72
EY1.9%
EPS(NY)8.83
Fwd EY2.17%
FCF(TTM)6.06
FCFY1.49%
OCF(TTM)7.37
OCFY1.81%
SpS24.49
BVpS43.37
TBVpS42.42
PEG (NY)3.65
PEG (5Y)2.46
Graham Number86.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROCE | 16.01% | ||
| ROIC | 13.95% | ||
| ROICexc | 20.73% | ||
| ROICexgc | 21.4% | ||
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% | ||
| FCFM | 24.75% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 79.72% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.46% | ||
| Profit Quality | 87.21% | ||
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 | ||
| Altman-Z | 40.01 |
F-Score8
WACC10.59%
ROIC/WACC1.32
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.56%
EBIT Next 3Y21.57%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%
INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.